Cargando…
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
BACKGROUND: Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation-positive metastatic castration-resistant PCa (mCRPC) patients following prior treatment with abiraterone, enzalutamide or docet...
Autores principales: | Fazekas, Tamás, Széles, Ádám D., Teutsch, Brigitta, Csizmarik, Anita, Vékony, Bálint, Váradi, Alex, Kói, Tamás, Lang, Zsolt, Ács, Nándor, Kopa, Zsolt, Hegyi, Péter, Hadaschik, Boris, Grünwald, Viktor, Nyirády, Péter, Szarvas, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638083/ https://www.ncbi.nlm.nih.gov/pubmed/36509931 http://dx.doi.org/10.1038/s41391-022-00626-2 |
Ejemplares similares
-
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Széles, Ádám, et al.
Publicado: (2022) -
Correction to: COVID-19 research: promising tracks leading to uro-oncology
por: Fazekas, Tamás, et al.
Publicado: (2020) -
COVID-19 research: promising tracks leading to uro-oncology
por: Tamás, Fazekas, et al.
Publicado: (2020) -
Lifestyle-, environmental-, and additional health factors associated with an increased sperm DNA fragmentation: a systematic review and meta-analysis
por: Szabó, Anett, et al.
Publicado: (2023) -
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022)